Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma.

Nelson, Blessie Elizabeth; Reddy, Neha K; Huse, Jason T; Amini, Behrang; Nardo, Mirella; Gouda, Mohamed; Weathers, Shiao-Pei; Subbiah, Vivek

Nelson, Blessie Elizabeth; Reddy, Neha K; Huse, Jason T; Amini, Behrang; Nardo, Mirella; Gouda, Mohamed; Weathers, Shiao-Pei; Subbiah, Vivek.

Afiliación

Nelson BE; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Reddy NK; Department of Internal Medicine, The University of Texas at Austin, Austin, TX, USA.
Huse JT; Department of Pathology and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Amini B; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nardo M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gouda M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Weathers SP; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Subbiah V; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. viveksubbiah@outlook.com.

NPJ Precis Oncol ; 7(1): 47, 2023 May 25.

Article en En | MEDLINE | ID: mdl-37231247

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: NPJ Precis Oncol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google